YU39396A - Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija - Google Patents

Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija

Info

Publication number
YU39396A
YU39396A YU39396A YU39396A YU39396A YU 39396 A YU39396 A YU 39396A YU 39396 A YU39396 A YU 39396A YU 39396 A YU39396 A YU 39396A YU 39396 A YU39396 A YU 39396A
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical formulation
preparation
medicine
obesity protein
isolated natural
Prior art date
Application number
YU39396A
Other languages
English (en)
Inventor
Juliana Maude Bue-Valleskey
Mark Louis Heiman
Thomas Wesley Stephens
C. Frank Tinsley
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU39396A publication Critical patent/YU39396A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms

Abstract

Opisana je upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka, kao i njegova farmaceutska formulacija koja je korisna kod lečenja ili prevencije stanja povezanih sa viškom neuropeptida Y. Takodje je opisana upotreba antagonista neuropeptida u kombinaciji sa proteinom gojaznosti za dobijanje leka.
YU39396A 1995-06-30 1996-06-28 Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija YU39396A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86195P 1995-06-30 1995-06-30
US73795P 1995-06-30 1995-06-30

Publications (1)

Publication Number Publication Date
YU39396A true YU39396A (sh) 1999-09-27

Family

ID=26668083

Family Applications (1)

Application Number Title Priority Date Filing Date
YU39396A YU39396A (sh) 1995-06-30 1996-06-28 Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija

Country Status (4)

Country Link
US (1) US5972888A (sh)
EP (1) EP0754464A3 (sh)
YU (1) YU39396A (sh)
ZA (1) ZA965346B (sh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
US6696409B1 (en) * 1996-06-05 2004-02-24 Prince Of Wales Medical Research Institute Limited (Powmr Ltd.) Neuropeptide Y agonists
US6297027B1 (en) * 1996-07-31 2001-10-02 Purina Mills, Inc. Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
US20050107327A1 (en) * 1997-12-19 2005-05-19 Hormos Medical Corporation Method for reducing overproduction of neuropeptide Y in an individual
TR200403328T2 (tr) * 1999-07-06 2005-03-21 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları.
WO2002003988A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
AU2002348131A1 (en) 2001-12-05 2003-06-23 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707490A1 (en) * 1993-06-18 1996-04-24 University Of Cincinnati Neuropeptide y antagonists and agonists
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5663192A (en) * 1994-10-20 1997-09-02 Eli Lilly And Company Heterocyclic neuropeptide Y receptor antagonists
EP0895781A3 (en) * 1994-10-20 1999-07-07 Eli Lilly And Company Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
US5569744A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
AU4766196A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Anti-obesity proteins
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
KR19990028388A (ko) * 1995-06-30 1999-04-15 피터 지. 스트링거 당뇨병 치료 방법

Also Published As

Publication number Publication date
EP0754464A2 (en) 1997-01-22
EP0754464A3 (en) 1999-06-30
US5972888A (en) 1999-10-26
ZA965346B (en) 1997-12-24

Similar Documents

Publication Publication Date Title
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
BR9814956A (pt) Inibidores de benzotiazol da tirosina cinase de proteìna
DK0714392T3 (da) Heterocykliske neurokinin-antagonister
NO20025450D0 (no) Ny farmasöytisk sammensetning
EE03741B1 (et) N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
SE9504661D0 (sv) New compounds
DE69738000D1 (de) Neue Arzneiformulierung enthaltend Budesonide
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
KR930701456A (ko) 세팔로스포린 및 동족체, 제조 및 제약학적 조성물
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
SE8804628D0 (sv) New compounds
YU39396A (sh) Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija
SE9402880D0 (sv) New peptide derivatives
SE0001916D0 (sv) Novel formulation
SE9504662D0 (sv) New compounds
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
DE69230644T2 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
FR2681320B1 (fr) Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
FR2688504B1 (fr) Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique.
PT1014951E (pt) Composicao de revestimento farmaceutica e metodo para a sua utilizacao
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina